葡萄糖类1受体激动剂:对于胆管癌的潜在游戏改变者
Ronnakrit Trakoonsenathong1,2,3,4, Ching-Feng Chiu4, Charupong Saengboonmee1,2,5
1Cho-Kalaphruek Excellent Research Project for Medical Students, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
World journal of gastroenterology
|October 1, 2024
概括
用于糖尿病的葡萄糖样-1受体 (GLP-1R) 激动剂与胆管癌 (CCA) 风险有相互矛盾的联系. 新出现的证据表明GLP-1R激动剂可能通过抑制GLP-1R表达来抑制CCA瘤生长.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 激动剂用于2型糖尿病,并显示出心血管方面的益处.
- 有关GLP-1R激动剂和癌症风险存在担忧,关于胆管癌 (CCA) 的流行病学数据相互矛盾.
- GLP-1R与细胞生长有关,高表达与CCA进展相关.
相关概念视频
01:24Glucagon-like Receptor Agonists
302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302
01:29Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
01:15Hypoglycemia and Glucagon
206
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
206